LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

Search

Arcutis Biotherapeutics Inc

Отворен

СекторЗдравеопазване

15.24 -1.87

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.11

Максимум

15.69

Ключови измерители

By Trading Economics

Приходи

9.2M

-16M

Продажби

16M

82M

Марж на печалбата

-19.491

Служители

342

EBITDA

6.7M

-12M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+38.27% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

186M

1.9B

Предишно отваряне

17.11

Предишно затваряне

15.24

Настроения в новините

By Acuity

50%

50%

172 / 372 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.08.2025 г., 22:51 ч. UTC

Печалби

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Rev $4.01B

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Adj EPS $1.84

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H EPS $1.82

27.08.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27.08.2025 г., 23:39 ч. UTC

Печалби

Correction to Nvidia Earnings Article -- WSJ

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27.08.2025 г., 22:58 ч. UTC

Печалби

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27.08.2025 г., 22:57 ч. UTC

Печалби

South32 FY Free Cash Flow $192 Million

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Total Capital Expenditure $1.35 Billion

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27.08.2025 г., 22:55 ч. UTC

Печалби

South32 Net Cash $123 Million at June 30

27.08.2025 г., 22:54 ч. UTC

Печалби

South32: Focused on Maintaining Strong Operating Momentum

27.08.2025 г., 22:53 ч. UTC

Печалби

South32: $144 Million Remains to be Returned to Shareholders Under Program

27.08.2025 г., 22:53 ч. UTC

Печалби

South32 Extends Capital Management Program for 12 Months

27.08.2025 г., 22:52 ч. UTC

Печалби

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27.08.2025 г., 22:45 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27.08.2025 г., 22:43 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27.08.2025 г., 22:43 ч. UTC

Печалби

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources Net Debt $123 Million at June 30

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources FY Underlying Ebitda $527.7 Million

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

38.27% нагоре

12-месечна прогноза

Среден 21.64 USD  38.27%

Висок 29 USD

Нисък 14.29 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

7

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

172 / 372 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.